Barrett’s esophagus is a precancerous condition that requires prompt intervention and management. Interventions for Barrett’s esophagus include regular monitoring, aggressive anti-reflux therapy, and endoscopic eradication therapy. Barrett’s esophagus is a condition in which columnar epithelium replaces the complex squamous epithelium covering the normal distal esophagus. The pyogenic columnar epithelium has the characteristics of both gastric and intestinal epithelium, and is prone to develop into esophageal adenocarcinoma, thus requiring early intervention. The aim of regular surveillance is to improve outcomes through early detection of heterogeneous hyperplasia or esophageal adenocarcinoma in order to allow timely and effective treatment. Many patients with Barrett’s esophagus have reflux esophagitis, and aggressive anti-reflux therapy may prevent cancer, so patients with Barrett’s esophagus are often treated with proton pump inhibitors (omeprazole, pantoprazole). If heterogeneous hyperplasia is present it is usually treated endoscopically, including endoscopic ablation techniques and endoscopic resection. Barrett’s esophagus suggests timely intervention to slow down the disease process.